<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566332</url>
  </required_header>
  <id_info>
    <org_study_id>WM1</org_study_id>
    <nct_id>NCT00566332</nct_id>
  </id_info>
  <brief_title>Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia</brief_title>
  <official_title>Randomized Trial Comparing the Efficacy of Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia,Lymphoplasmacytic Lymphoma or Splenic Marginal Zone Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Study Group on Chronic Lymphoid Leukemia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Département de Biostatistiques et Informatique Médicale DBIM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>French Study Group on Chronic Lymphoid Leukemia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Waldenström's macroglobulinaemia (WM) is a lymphoproliferative disorder characterized by a
      monoclonal IgM paraprotein and morphological evidence of lymphoplasmacytic lymphoma: the
      cells are IgM+, IgD+, CD19+ and CD20+ but usually CD5-, CD10- and CD23-. The treatment
      efficacy is difficult to assess because of the lack of clear diagnostic criteria , good
      response criteria, and of randomized trials.

      The actual treatment is Chlorambucil, an alkylating agent. A purine analogue such as
      Fludarabine has proven its efficacy on 30 % to 80 % as first line therapy

      This study is a phase II b open, prospective, international multicenter trial (England, Dr
      Johnson, Dr Catovsky, Australia: Dr Seymour) promoted by the French Cooperative Group on
      Chronic Lymphoid Leukemia in untreated WM, or closely related disorders ( Lymphoplasmacytic
      lymphoma or splenic marginal zone lymphoma). 366 patients must be included, among them 180
      patients in France. Patients will be stratified according to the lymphoproliferative
      disorder.

      The patients will receive Chlorambucil by oral route for 10 days every 28 days (12 cycles) (8
      MG/M², 6 MG/M² if patient is more than 75 years old) or Fludarabine by oral route for 5 days
      every 28 days (6 cycles) (40MG/M², 30 MG/M² if patient is more than 75 years old).

      The primary objective is to compare the efficacy (response rate) of Chlorambucil to
      Fludarabine in previously untreated patients. The secondary objectives are the duration of
      response, the improvement of hematological parameters, the toxicity, the quality of life, the
      event free survival and the overall survival.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient overall response</measure>
    <time_frame>At the end of treatment whether 6 or 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biological study</measure>
    <time_frame>Whether 6 or 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Whether 6 or 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment toxicity</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">414</enrollment>
  <condition>Waldenström Macroglobulinemia</condition>
  <condition>Lymphoplasmacytic Lymphoma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chlorambucil 8mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fludarabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorambucil</intervention_name>
    <description>Chlorambucil 8 mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months By oral route</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 40 mg/m² (30 mg/m² if patient aged more than 75 years old) 5 days every 28 days during 6 cycles By oral route</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Established diagnosis of Waldenström macroglobulinemia (the 2nd Workshop on Waldenstrom's
        macroglobulinemia) or Lymphoplasmacytic lymphoma or Splenic Marginal Zone Lymphoma, needing
        a treatment

          -  Life expectancy &gt; 6 months

          -  Creatinine &lt; 200 µmol/l

          -  SGPT and SGOT &lt; 2x ULN

          -  A negative direct Coombs test

          -  Written informed consent

        Exclusion Criteria:

          -  Past chemotherapy/radiotherapy/immunotherapy prior to the study for Waldenström
             macroglobulinemia

          -  Previous malignancy less than 5 years ago except carcinoma in situ of the cervix and
             non-melanoma skin cancer

          -  Positive HIV serology

          -  Active Hepatitis B or C

          -  Lactation/pregnancy

          -  Impossible good compliance with the study protocol

          -  Active infection not controlled

          -  Psychological condition hampering understanding of the study

          -  Transformation into large B cell lymphoma

          -  Peripheral neuropathy &gt; grade II
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Véronique LEBLOND, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Study Group on Chronic Lymphoid Leukemia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital La Pitié-Salpêtrière. 47-83 Bd de l'hôpital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2007</study_first_submitted>
  <study_first_submitted_qc>November 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2007</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Waldenström Macroglobulinemia</keyword>
  <keyword>Lymphoplasmacytic lymphoma</keyword>
  <keyword>Splenic Marginal Zone Lymphoma</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Chlorambucil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Chlorambucil</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

